What is happening with BMRN stock?
BioMarin Pharmaceutical (BMRN) is set to post its Q2 2026 quarterly earnings after the market closes on Monday, August 3, 2026. Analysts are forecasting earnings of $0.96 per share on revenue of approximately $932 million. Despite recent adjustments to price targets by some firms, the consensus analyst rating remains a "Moderate Buy," and institutional investors maintain a very high ownership stake in the company. The upcoming earnings call will provide critical insights into the company's current financial health and future growth prospects for its specialized therapeutic pipeline.
Related FAQs
BioMarin Pharmaceutical Inc. (BMRN) carries a consensus Buy rating from healthcare and biotechnology analysts, featuring average 12-month price targets hovering around $88.65 per share.
Yes, Brookfield Corporation has split its common stock numerous times over several decades of corporate growth.
BioMarin Pharmaceutical is considered a strong payer within the biotechnology industry, offering salaries that align with high-demand roles in pharmaceutical research and development.
BioMarin Pharmaceutical Inc.
Yes, BioNTech has active and ongoing clinical trials for investigational mRNA-based cancer vaccines.
Identifying the best pharmaceutical stocks to purchase depends heavily on prevailing macroeconomic conditions, clinical trial pipeline catalysts, patent expiration timelines, and individual investor risk profiles.
Wall Street equity research analysts generally evaluate BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as a favorable "buy" rather than a sell.
Determining whether BioMarin Pharmaceutical represents a sound investment involves weighing its strong fundamentals in the rare disease biotechnology market against near-term sector volatility.
BioMarin has not implemented widespread corporate downsizing due to financial distress, but like many large biopharmaceutical enterprises, it occasionally executes targeted workforce adjustments and organizational realignments.
Financial market consensus classifies BioMarin Pharmaceutical primarily as a "buy" to "hold" candidate rather than a sell.
BioMarin operates primarily as a biotechnology company, though its comprehensive scope bridges both the biotech and pharmaceutical sectors.
Wall Street analysts following BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) estimate an average 1-year consensus price target of roughly $87.83 to $90.92. Forecast ranges span from a low target of $50.50 up to a high estimate of $126.00.
Black Hills Energy employs nearly 3,000 dedicated professionals across its operating footprint. As a prominent electric and natural gas utility subsidiary, the company delivers safe and reliable energy to over 1.
BioMarin Pharmaceutical is a global biotechnology company that specializes in developing first-in-class and best-in-class therapeutics for severe rare, genetically defined conditions and lysosomal storage disorders.
BioMarin Pharmaceutical Inc. is headquartered in San Rafael, California, United States.
BioMarin Pharmaceutical Inc. is an entirely legitimate, publicly traded, and globally respected biopharmaceutical enterprise.
BioMarin Pharmaceutical specializes in developing and commercializing advanced, breakthrough biotherapeutics for rare genetic and ultra-rare metabolic disorders.
Evaluating whether BioMarin stock is undervalued depends on an investor's perspective regarding its long-term growth prospects in the rare disease treatment market.
Examining the stock volatility of Broadstone Net Lease, Inc.—a real estate investment trust specializing in single-tenant net lease commercial properties—shows a low to moderate volatility profile.
BioMarin Pharmaceutical possesses a promising future driven by its specialized portfolio of innovative therapies targeting rare genetic diseases and orphan conditions.